Table 3 Comparison of the characteristics of the patients with juvenile Behçet’s disease who were and were not treated with anti-tumor necrosis factor-alpha therapy

Male gender, n (%)

3

(50.0)

19

(38.8)

0.674

Age at disease onset (years)

7.0

(0.25–13.0)

12

(0.1–16.0)

0.029*

Age at diagnosis (years)

7.5

(2.0–13.0)

13

(0.1–16.0)

0.012*

Time to diagnosis (years)

1

(0.0–2.8)

0

(0.0–8.0)

0.553

 Recurrent oral aphthous ulcers

6

(100.0)

49

(100.0)

1.000

 Genital ulceration

5

(83.3)

33

(67.3)

0.654

 Skin involvement

2

(33.3)

18

(36.7)

1.000

 Ocular involvement

2

(33.3)

13

(26.5)

0.638

 Neurologic signs

1

(16.7)

2

(4.1)

0.298

 Vascular signs

0

(0.0)

1

(2.0)

1.000

 Gastrointestinal symptoms

4

(66.7)

11

(22.4)

0.041*

 Arthritis/arthralgia

4

(66.7)

12

(24.5)

0.053

 WBC count (× 10³/ΜL)

11.8

(5.0–18.0)

8.8

(3.8–18.6)

0.339

 Hemoglobin, g/L

11.5

(10.3–14.1)

13.1

(10–14.7)

0.060

 Platelet count (× 10³/ΜL)

386

(212.0–570.0)

294.5

(170.0–576.0)

0.098

 C-reaction protein (mg/dL)

6

(2.5–10.5)

0.4

(0.0–20.0)

0.025*

 ESR (mm/h)

29

(9.0–50.0)

18.5

(2.0–90.0)

0.314

 Prednisolone, n (%)

6

(100)

35

(71.4)

0.320

 Colchicine, n (%)

2

(33.3)

28

(57.1)

0.394

 NSAIDs, n (%)

3

(50)

14

(28.6)

0.359

 DMARDs^‡, n (%)

4

(66.7)

21

(42.9)

0.394

 Immunosuppressive agents^#, n (%)

6

(100)

15

(30.6)

0.002*

 Rheumatologic drugs, n

4

(2–7)

2

(0–6)

0.010*